NCT04707729 (ROX-1) is a NA clinical trial of ROX index algorithm in Acute Hypoxemic Respiratory Failure, sponsored by Hospital Universitari Vall d'Hebron Research Institute.

Who is sponsoring NCT04707729?

NCT04707729 is sponsored by Hospital Universitari Vall d'Hebron Research Institute.

What drugs are being tested in NCT04707729?

Interventions in NCT04707729: ROX index algorithm.

What condition does NCT04707729 study?

NCT04707729 studies Acute Hypoxemic Respiratory Failure.

Is NCT04707729 still recruiting?

NCT04707729 is currently recruiting now. Last updated 15 August 2024.

Last reviewed 2024-08-15 · How we verify

NCT04707729: ROX-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ROX Index for the Timing of Intubation in Nasal High Flow

Recruiting now NA Last updated 15 August 2024

What this trial tests

NA trial testing ROX index algorithm in Acute Hypoxemic Respiratory Failure in 630 participants. Currently enrolling.

Timeline

9 December 2020

Primary endpoint
31 December 2024

30 June 2025

Quick facts

Lead sponsor	Hospital Universitari Vall d'Hebron Research Institute
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	630
Start date	9 December 2020
Primary completion	31 December 2024
Estimated completion	30 June 2025
Sites	12 locations across China, United States, Spain

Drugs / interventions tested

ROX index algorithm

Conditions studied

Acute Hypoxemic Respiratory Failure — all drugs for Acute Hypoxemic Respiratory Failure →

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Who can join

Adults 18 to 120, any sex, with Acute Hypoxemic Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Late or delayed intubation in patients with acute hypoxemic respiratory failure (AHRF) treated with nasal high flow (NHF) is associated with increased patient mortality. The ROX index has been designed and validated to predict outcome of NFH therapy by identifying those patients with a high risk of NHF failure and those with a high probability of success. Whether or not the ROX index may improve patient outcome remains to be shown. To do so, a strategy using the ROX index must lead to earlier intubation than commonly-used criteria. The objective of the ROX-1 trial is to assess whether the use of an algorithm incorporating the ROX index to standard of care for the time to intubation in patients with AHRF supported with NHF isassociated with an increase in the proportion of patients who are intubated within the first 12 hours among those patients who fail on NHF.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The use of high-flow nasal oxygen.
Maggiore SM, Grieco DL, Lemiale V. · · 2023 · cited 17× · PMID 37079086 · DOI 10.1007/s00134-023-07067-y
Sepsis and acute respiratory failure in patients with cancer: how can we improve care and outcomes even further?
Lyons PG, McEvoy CA, Hayes-Lattin B. · · 2023 · cited 4× · PMID 37641516 · DOI 10.1097/mcc.0000000000001078

Verify or expand the search:

Other recruiting trials for Acute Hypoxemic Respiratory Failure

Currently open trials in the same condition.

NCT07334379 — Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptom · Phase 2 · recruiting
NCT06921655 — Targeting prEssure-Muscle-index to Avoid Ventilatory Over-Assistance During Pressure Support Ventilation · NA · recruiting
NCT06931938 — Awake Prone Positioning in Spontaneous Breathing Patients With Acute Hypoxic Respiratory Failure Due to Pneumonia · NA · recruiting
NCT07178483 — Evaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure · active not recruiting
NCT06815523 — Prediction of Duration of Mechanical Ventilation in Acute Hypoxemic Respiratoty Failure · active not recruiting

Other Hospital Universitari Vall d'Hebron Research Institute trials

Trials by the same sponsor.

NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04707729 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
Last refreshed: 15 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04707729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing